(Concizumab)Biosimilar Reference Antibody-GS40146 新品

货号：GS40146

Concizumab is an investigational humanized monoclonal antibody developed as a novel prophylactic treatment for hemophilia A and B, regardless of inhibitor status. It represents a new class of therapy known as an anti-TFPI (tissue factor pathway inhibitor) antibody. Unlike traditional factor replacement therapies, concizumab works by modulating the body's own natural coagulation pathway to enhance thrombin generation. It is administered via subcutaneous injection, offering a significant convenience advantage over intravenous factor products. Clinical trials have demonstrated its potential to reduce bleeding episodes effectively.